Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to a late
diagnosis and poor response to available treatments. There is a need to identify …

Pancreatic cancer is an aggressive malignancy, which generally respond poorly to
chemotherapy. Hence, novel agents that are safe and effective are highly needed. The aim …

Pancreatic cancer is one of the most deadly cancers with a nearly 95% mortality rate. The
poor response of pancreatic cancer to currently available therapies and the extremely low …

Aim Pancreatic cancer (PC) is one of the most aggressive tumors with dismal survival and a
high death rate due to chemotherapeutic failure. P-glycoprotein (P-gp) plays a pivotal role in …

Survival rate for pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is poor, with
about 80% of patients presenting with the metastatic disease. Gemcitabine, the standard …

There is an unmet need to develop new agents or strategies against therapy resistant
pancreatic cancer (PanCA). Recent studies from our laboratory showed that STAT3 …

Gemcitabine is currently the best known chemotherapeutic option available for pancreatic
cancer, but the tumor returns de novo with acquired resistance over time, which becomes a …

Gemcitabine resistance will occur by time after the initial response in pancreatic cancer.
Ginkgolide B (GB), a major terpene lactone component of Ginkgo biloba leaves, is a highly …

Simple Summary The BET bromodomain inhibitor JQ1 slows tumor growth in preclinical
models of pancreatic cancer. However, as a single agent, it does not induce tumor …

Objectives Pancreatic ductal adenocarcinoma remains as a chemoresistant disease with the
poorest prognosis. Gemcitabine has been the standard treatment during the last decade …